Global Computational Biology Market is valued at USD 4.71 Billion in 2022 and is projected to attain a value of USD 17.46 Billion by 2030 at a CAGR of 17.80% during the forecast period, 2022–2028. Computational Biology is an inter-disciplinary applied science that studies biological systems using mathematical, theoretical, and computer simulation models based on basic biology concepts. The rise in R&D for drug development, need for predictive models, use in population-based sequencing efforts like the human genome project, and government financing are all driving market expansion.
Computational Biology Market Size, 2022 To 2030 (USD Billion)
Computational Biology uses computer-aided biological models to generalize methods and properly depict simulations in virtual space to review difficulties in biological models. Computational genetics is a branch of Computational Biology that studies genomic homology and internal biological systems through genome sequencing. One of the most notable examples is the Human Genome Project, which successfully sequenced the whole human genome. Computational Biology is used in neurology to see and comprehend three-dimensional simulation models of the brain by mapping complicated interconnected pathways. In the drug development process, computational pharmacology makes use of computer-aided visualization techniques to simulate advanced drug-drug interactions.
Report Coverage & Deliverables
- Competitive benchmarking
- Historical data & forecasts
- Company revenue shares
- Regional opportunities
- Latest trends & dynamics
- Power BI Report (Dashboard)
Rising R&D Funding and Growing Initiatives
Growing drug discovery R&D, demand for predictive models, use in population-based sequencing efforts like the human genome project, and government financing are all driving the market forward. For example, in March 2019, Ambrx Inc., a clinical-stage bio-pharmaceutical firm specializing in protein treatments, struck a research and development agreement with BeiGene, Ltd., a commercial-stage pharmaceutical company specializing in immuno-oncology medication development. Ambrx has developed a unique Expanded Genetic Code platform that allows non-natural amino acids to be incorporated into protein sequences in E. coli and Chinese Hamster Ovary (CHO) cells. Both companies will use Ambrx's drug discovery platforms in conjunction with the latter's expertise and resource pool to produce clinically advanced biologic products.
The Global Computational Biology Market has been segmented by Application into Cellular & Biological Simulation, Drug Discovery & Disease Modelling, Pre-clinical Drug Development and Clinical Trials. By Services, into In-house and Contract. By End-Use into Academics, Industry and Commercial. Based on Region, the Computational Biology Market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Below tree is interactive. You can click the nodes to get more information.
The Computational Biology market is divided into five categories based on application: cellular and biological simulation, drug discovery and illness modelling, pre-clinical drug development, clinical trials, and human body simulation software. Computational genomics and proteomics, pharmacogenomics, and other types of cellular and biological simulation exist. Target identification, target validation, lead finding, and optimization are all parts of drug discovery and disease modelling. Pharmacokinetics and pharmacodynamics are two subcategories of pre-clinical development. Clinical trials are divided into three phases: phase I, phase II, and phase III.
North America to Continue Dominating the Computational Biology Market
North America, Europe, and Asia Pacific accounted for the greatest proportion of the Computational Biology market in 2021. Factors such as the increase in the number of well-established Computational Biology companies and research institutes in the United States and Canada, a large number of ongoing research studies, and the overall growth of the healthcare sector on a global scale are among the few factors expected to contribute to the market's growth. One of the primary causes leading to the growing demand for Computational Biology techniques and technologies among academic and research organisations, as well as healthcare firms in North America, is increased R&D spending.
Some of the key players in the Computational Biology market are Chemical Computing Group Inc.; Compugen Ltd.; Simulation Plus Inc.; Genedata AG; Certara; Insilico Biotechnology AG; Accelrys; Rhenovia Pharma SAS; Entelos; Nimbus Discovery LLC; and Rhenovia Pharma SAS.
The Computational Biology market is segmented as follows:
- Application (Cellular & Biological Simulation, Drug Discovery & Disease Modelling, Preclinical Drug Development, Clinical Trials, Human Body Simulation Software)
- Services (In-house, Contract)
- End-Use (Academics, Industry, Commercial)
- Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa)
|Regions & Countries Covered
- North America - (U.S., Canada, Mexico)
- Europe - (U.K., France, Germany, Italy, Spain, Rest Of Europe)
- Asia Pacific - (China, Japan, India, South Korea, South East Asia, Rest Of Asia Pacific)
- Latin America - (Brazil, Argentina, Rest Of Latin America)
- Middle East & Africa - (GCC Countries, South Africa, Rest Of Middle East & Africa)
- Dassault Systèmes SE (France)
- Chemical Computing Group ULC (Canada)
- Genedata AG (Switzerland)
- Instem PLC (UK)
- Compugen Ltd (Israel).
||Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST
analysis, value chain analysis, regulatory landscape, technology landscape, patent analysis, market
attractiveness analysis by segments and North America, company market share analysis, and COVID-19
Pricing and purchase options
||Avail of customized purchase options to meet your exact research needs. Explore purchase options
The Computational Biology market tabulated as below: